Developer docs
API playgroundTry for free, no card

Search company profiles

Skye Biologics

Full company profile

uuid000a5cl

Namestring
Skye Biologics
Legal namestring
Skye Biologics Holdings, LLC
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Skye Biologics Holdings, LLC is a privately held regenerative medicine company headquartered in El Segundo, California, that develops, processes, and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue. Its core technology, the proprietary HydraTek® BioAware® preservation system, processes placental connective tissue matrix without lyophilization, heat-baking, or chemical cross-linking, preserving natural biomechanical structure and enabling room-temperature storage with a five-year shelf life. The commercial portfolio spans three categories: advanced wound care products (WoundFix™, WoundPlus™, E-Graft™), surgical barrier membranes (ActiveBarrier® 200 and 2000), and ocular allografts (OculoMatrix® and VisiDisc® in thin and thick configurations). The company serves orthopedic, spine, sports medicine, ophthalmology, wound care, urology, gynecology, plastic surgery, and general surgery specialists across the United States and selectively in Canada, with a stated pipeline of regenerative therapeutics targeting musculoskeletal and high-unmet-need indications.

The company operates a vertically integrated supply chain through majority ownership of Human Regenerative Technologies (HRT), an AATB-licensed tissue bank that processes its allograft products. Skye generates revenue through one-time sale of tissue allograft units via a hybrid go-to-market combining direct sales to physicians and hospitals, independent sales representatives and distributors, approved contracts at regional, national, and government facilities, and quote-based phone/email ordering supported by dedicated physician and customer portals. A physician-collaboration patient registry of 5,000+ patients underpins clinical evidence generation, and the company cites FDA HCT/P compliance plus state tissue processor licenses in seven jurisdictions as its regulatory foundation.

Short descriptiontext

Skye Biologics is a privately held regenerative medicine company that develops and commercializes ECM tissue allograft products from age-zero placental tissue using its proprietary HydraTek® preservation process, serving wound care, surgical, and ocular specialists across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEl Segundo, United States
HQ citystring
El Segundo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, tissue allografts, wound care products, extracellular matrix, amniotic membrane
Industry5 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical Appliance and Supplies Manufacturing339113
  • Blood and Organ Banks621991
SIC code4 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Medicine Tissue Allografts
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Tissue Allograft Products
TypeOne Time License
Description

Skye Biologics commercializes ECM allograft products including wound care products (WoundFix™, WoundPlus™, E-Graft™), surgical membranes (ActiveBarrier® 200, ActiveBarrier® 2000), and ocular products (OculoMatrix®, VisiDisc®). Products are sold as one-time tissue transplants for surgical and wound care applications.

skyebiologics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based pricing for tissue allograft products
ModelOtherBilling cadencePay-as-you-go
Notes

Direct ordering via phone (310) 616-3141 or email orders@skyebiologics.com

skyebiologics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1HydraTek®
Description

Proprietary tissue processing technology that preserves extracellular matrix (ECM) and produces the industry's most advanced allograft products with BioAware® technology

skyebiologics.com
+8 more records
Core offering1 text field

Skye Biologics processes and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue using its proprietary HydraTek® BioAware® preservation technology. The portfolio includes Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™), Surgical Products (ActiveBarrier® 200 and 2000), and Ocular Products (OculoMatrix® and VisiDisc® in thin and thick configurations), sold to physicians, hospitals, and healthcare facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 250,000 tissue-repair treatments performed nationwide with first generation tissue implants
+2 more records
Product overview1 text field

Skye Biologics is a vertically integrated regenerative medicine company commercializing ECM (extracellular matrix) allograft products preserved using its proprietary HydraTek® technology. The product portfolio spans three main categories: Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™) for acute and chronic wound management; Surgical Products (ActiveBarrier® 200, ActiveBarrier® 2000) for protective barrier applications; and Ocular Products (OculoMatrix® & VisiDisc® in Thin and Thick configurations) for ophthalmic procedures. All products utilize placental tissue from age-zero donors, processed through the BioAware® preservation system to maintain natural tissue structure and integrity.

Product and service7 records
1WoundFix™
CategoryAdvanced Wound Product
Description

Dehydrated amniotic membrane tissue allograft intended for homologous use as wound coverings in the management of acute and chronic wounds.

2WoundPlus™
CategoryAdvanced Wound Product
Description

Dehydrated amniotic membrane tissue allograft with natural rippled surface that can make it more ideal for self-adherence, intended for homologous use as wound coverings.

3E-Graft™
CategoryAdvanced Wound Product
Description

Dehydrated amniotic membrane tissue allograft with natural macro-texture surface that may assist in better adherence to the wound, intended for homologous use as wound coverings.

4ActiveBarrier® 200
CategorySurgical Product
Description

Thick surgical membrane allograft (200 microns) with robust handling characteristics, preserving complete ECM via HydraTek® process. Provides natural adherence without need for sutures or fixation and can be applied in either direction.

5ActiveBarrier® 2000
CategorySurgical Product
Description

Thickest surgical membrane allograft from Skye, providing robust handling and alternative options. Can be sutured if desired. Fresh-frozen storage required.

6OculoMatrix® & VisiDisc® Thin
CategoryOcular Product
Description

Thinner amniotic membrane graft (45 microns) derived from amnion membrane, providing versatile graft for most applications with ideal handling dry or wet.

7OculoMatrix® & VisiDisc® Thick
CategoryOcular Product
Description

Chorion-based amniotic membrane graft (200 microns) providing alternative handling characteristics and improved visibility for minimally invasive applications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

HRT is a sister company and AATB licensed tissue bank that processes tissue allograft products for Skye Biologics through its HydraTek® technology. Skye Biologics Holdings became the majority owner of HRT in December 2018. HRT serves as the primary allograft tissue processor for Skye Orthobiologics, LLC's placental and amniotic tissue allograft offering.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical device incumbent with a substantial advanced wound management portfolio that overlaps with Skye's wound care allografts. Significantly larger scale and broader product breadth; competing primarily through conventional wound dressings and skin substitutes.

TypeBroad incumbent
Description

Convatec is a global wound care and ostomy incumbent with adjacent biologic and skin-substitute offerings (e.g., InnovaMatrix). Larger scale than Skye; competes for the same hospital and outpatient wound care budgets.

TypeEmerging player
Description

Surgenex markets amniotic membrane and umbilical cord allografts (e.g., SurForce, SurGraft) targeting wound care, orthopedics, and pain management. Smaller and emerging peer with overlapping placental allograft technology and customer segments.

TypeBroad incumbent
Description

Coloplast operates a sizable wound and skin care business alongside its core ostomy and continence franchises. Comparable in wound care end markets but at materially larger scale and broader portfolio.

TypeDirect peer
Description

Celularity develops and commercializes placental-derived allogeneic cellular and tissue products for wound care and regenerative medicine. Directly comparable technology base (placental tissue) and overlapping wound care commercial focus.

TypeBroad incumbent
Description

Integra is a diversified medical device incumbent with a regenerative technologies segment including AmnioExcel and PriMatrix wound care allografts, plus a broad neurosurgery/orthopedics portfolio. Comparable on wound and surgical membrane products but operates at much greater scale and breadth.

TypeDirect peer
Description

Anika commercializes regenerative therapies including hyaluronic-acid-based viscosupplementation and surgical regenerative products (e.g., Tactoset, Bone Repair). Comparable on orthopedic regenerative medicine focus and surgical-channel distribution.

TypeDirect peer
Description

Organogenesis is a publicly-traded regenerative medicine company with a portfolio spanning wound care (Apligraf, Dermagraft) and surgical/orthopedic biologics (NuShield, PuraPly). Directly competes with Skye's wound and surgical membrane products in the same hospital/physician channels.

TypeDirect peer
Description

MiMedx is a direct competitor in placental tissue allografts (EpiFix, AmnioFix) serving wound care, surgical, and orthopedic applications. Strong overlap with Skye's HydraTek-based product line, target specialties, and channel approach (physicians, hospitals).

TypeEmerging player
Description

Cook Biotech develops and manufactures extracellular matrix-based medical devices (e.g., OASIS wound matrix, Biodesign surgical products). Comparable ECM/biologic platform serving wound care and surgical specialties.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Skye Biologics

Regenerative Medicine Tissue Allograftsskyebiologics.com

Skye Biologics is a privately held regenerative medicine company that develops and commercializes ECM tissue allograft products from age-zero placental tissue using its proprietary HydraTek® preservation process, serving wound care, surgical, and ocular specialists across the United States.

What Skye Biologics does

Skye Biologics Holdings, LLC is a privately held regenerative medicine company headquartered in El Segundo, California, that develops, processes, and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue. Its core technology, the proprietary HydraTek® BioAware® preservation system, processes placental connective tissue matrix without lyophilization, heat-baking, or chemical cross-linking, preserving natural biomechanical structure and enabling room-temperature storage with a five-year shelf life. The commercial portfolio spans three categories: advanced wound care products (WoundFix™, WoundPlus™, E-Graft™), surgical barrier membranes (ActiveBarrier® 200 and 2000), and ocular allografts (OculoMatrix® and VisiDisc® in thin and thick configurations). The company serves orthopedic, spine, sports medicine, ophthalmology, wound care, urology, gynecology, plastic surgery, and general surgery specialists across the United States and selectively in Canada, with a stated pipeline of regenerative therapeutics targeting musculoskeletal and high-unmet-need indications.

The company operates a vertically integrated supply chain through majority ownership of Human Regenerative Technologies (HRT), an AATB-licensed tissue bank that processes its allograft products. Skye generates revenue through one-time sale of tissue allograft units via a hybrid go-to-market combining direct sales to physicians and hospitals, independent sales representatives and distributors, approved contracts at regional, national, and government facilities, and quote-based phone/email ordering supported by dedicated physician and customer portals. A physician-collaboration patient registry of 5,000+ patients underpins clinical evidence generation, and the company cites FDA HCT/P compliance plus state tissue processor licenses in seven jurisdictions as its regulatory foundation.

Skye Biologics firmographics

Firmographics
Name
Skye Biologics
Legal name
Skye Biologics Holdings, LLC
Website
https://skyebiologics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Skye Biologics is a privately held regenerative medicine company that develops and commercializes ECM tissue allograft products from age-zero placental tissue using its proprietary HydraTek® preservation process, serving wound care, surgical, and ocular specialists across the United States.
Ownership category
akta.pro rank

Skye Biologics industry classification

Industry
Product category
Regenerative Medicine Tissue Allografts
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Tissue allografts
  • Wound care products
  • Extracellular matrix
  • Amniotic membrane

Where Skye Biologics is headquartered

Location

Headquarters

HQ city
El Segundo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Skye Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Tissue Allograft Products: Skye Biologics commercializes ECM allograft products including wound care products (WoundFix™, WoundPlus™, E-Graft™), surgical membranes (ActiveBarrier® 200, ActiveBarrier® 2000), and ocular products (OculoMatrix®, VisiDisc®). Products are sold as one-time tissue transplants for surgical and wound care applications.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for tissue allograft products

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Skye Biologics product offering

Product offering

Core offering

Skye Biologics processes and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue using its proprietary HydraTek® BioAware® preservation technology. The portfolio includes Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™), Surgical Products (ActiveBarrier® 200 and 2000), and Ocular Products (OculoMatrix® and VisiDisc® in thin and thick configurations), sold to physicians, hospitals, and healthcare facilities.

Product overview

Skye Biologics is a vertically integrated regenerative medicine company commercializing ECM (extracellular matrix) allograft products preserved using its proprietary HydraTek® technology. The product portfolio spans three main categories: Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™) for acute and chronic wound management; Surgical Products (ActiveBarrier® 200, ActiveBarrier® 2000) for protective barrier applications; and Ocular Products (OculoMatrix® & VisiDisc® in Thin and Thick configurations) for ophthalmic procedures. All products utilize placental tissue from age-zero donors, processed through the BioAware® preservation system to maintain natural tissue structure and integrity.

Differentiator

Problem solved

Functional benefit

Brands

  • HydraTek®: Proprietary tissue processing technology that preserves extracellular matrix (ECM) and produces the industry's most advanced allograft products with BioAware® technology
  • BioAware®
  • WoundFix™
  • WoundPlus™
  • E-Graft™
  • ActiveBarrier®
  • OculoMatrix®
  • VisiDisc®
  • Excellerate®

Products and services

  • WoundFix™ Dehydrated amniotic membrane tissue allograft intended for homologous use as wound coverings in the management of acute and chronic wounds.
  • WoundPlus™ Dehydrated amniotic membrane tissue allograft with natural rippled surface that can make it more ideal for self-adherence, intended for homologous use as wound coverings.
  • E-Graft™ Dehydrated amniotic membrane tissue allograft with natural macro-texture surface that may assist in better adherence to the wound, intended for homologous use as wound coverings.
  • ActiveBarrier® 200 Thick surgical membrane allograft (200 microns) with robust handling characteristics, preserving complete ECM via HydraTek® process. Provides natural adherence without need for sutures or fixation and can be applied in either direction.
  • ActiveBarrier® 2000 Thickest surgical membrane allograft from Skye, providing robust handling and alternative options. Can be sutured if desired. Fresh-frozen storage required.
  • OculoMatrix® & VisiDisc® Thin Thinner amniotic membrane graft (45 microns) derived from amnion membrane, providing versatile graft for most applications with ideal handling dry or wet.
  • OculoMatrix® & VisiDisc® Thick Chorion-based amniotic membrane graft (200 microns) providing alternative handling characteristics and improved visibility for minimally invasive applications.

Quantifiable outcome

  • Over 250,000 tissue-repair treatments performed nationwide with first generation tissue implants
  • +2 more outcomes

Companies that use Skye Biologics

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Skye Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Skye Biologics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Human Regenerative Technologies (HRT)coreOthersHRT is a sister company and AATB licensed tissue bank that processes tissue allograft products for Skye Biologics through its HydraTek® technology. Skye Biologics Holdings became the majority owner of HRT in December 2018. HRT serves as the primary allograft tissue processor for Skye Orthobiologics, LLC's placental and amniotic tissue allograft offering.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Skye Biologics competitors and assessment

Company assessment

Broad incumbents

  • Smith+Nephew: Global medical device incumbent with a substantial advanced wound management portfolio that overlaps with Skye's wound care allografts. Significantly larger scale and broader product breadth; competing primarily through conventional wound dressings and skin substitutes.
  • Convatec: Convatec is a global wound care and ostomy incumbent with adjacent biologic and skin-substitute offerings (e.g., InnovaMatrix). Larger scale than Skye; competes for the same hospital and outpatient wound care budgets.
  • Coloplast: Coloplast operates a sizable wound and skin care business alongside its core ostomy and continence franchises. Comparable in wound care end markets but at materially larger scale and broader portfolio.
  • Integra LifeSciences: Integra is a diversified medical device incumbent with a regenerative technologies segment including AmnioExcel and PriMatrix wound care allografts, plus a broad neurosurgery/orthopedics portfolio. Comparable on wound and surgical membrane products but operates at much greater scale and breadth.

Emerging players

  • Surgenex: Surgenex markets amniotic membrane and umbilical cord allografts (e.g., SurForce, SurGraft) targeting wound care, orthopedics, and pain management. Smaller and emerging peer with overlapping placental allograft technology and customer segments.
  • Cook Biotech: Cook Biotech develops and manufactures extracellular matrix-based medical devices (e.g., OASIS wound matrix, Biodesign surgical products). Comparable ECM/biologic platform serving wound care and surgical specialties.

Direct peers

  • Celularity: Celularity develops and commercializes placental-derived allogeneic cellular and tissue products for wound care and regenerative medicine. Directly comparable technology base (placental tissue) and overlapping wound care commercial focus.
  • Anika Therapeutics: Anika commercializes regenerative therapies including hyaluronic-acid-based viscosupplementation and surgical regenerative products (e.g., Tactoset, Bone Repair). Comparable on orthopedic regenerative medicine focus and surgical-channel distribution.
  • Organogenesis Holdings: Organogenesis is a publicly-traded regenerative medicine company with a portfolio spanning wound care (Apligraf, Dermagraft) and surgical/orthopedic biologics (NuShield, PuraPly). Directly competes with Skye's wound and surgical membrane products in the same hospital/physician channels.
  • MiMedx Group: MiMedx is a direct competitor in placental tissue allografts (EpiFix, AmnioFix) serving wound care, surgical, and orthopedic applications. Strong overlap with Skye's HydraTek-based product line, target specialties, and channel approach (physicians, hospitals).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Skye Biologics social profiles

Digital presence

Skye Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Skye Biologics leadership team

Management profile

Number of profiles

Skye Biologics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Skye Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Skye Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skye Biologics

What does Skye Biologics do?

Skye Biologics processes and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue using its proprietary HydraTek® BioAware® preservation technology. The portfolio includes Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™), Surgical Products (ActiveBarrier® 200 and 2000), and Ocular Products (OculoMatrix® and VisiDisc® in thin and thick configurations), sold to physicians, hospitals, and healthcare facilities.

Is Skye Biologics a public or private company?

Skye Biologics is a private company. It is classified as unknown and is currently operating.

When was Skye Biologics founded?

Skye Biologics was founded in 2010. It employs 11 to 50 people.

Where is Skye Biologics based?

Skye Biologics is headquartered in El Segundo, United States, in the North America region.

How does Skye Biologics make money?

One revenue line is on record: tissue Allograft Products.

Who are Skye Biologics's main competitors?

Broad incumbents on record are Smith+Nephew, Convatec, Coloplast and Integra LifeSciences. Emerging players are Surgenex and Cook Biotech. Direct peers are Celularity, Anika Therapeutics, Organogenesis Holdings and MiMedx Group.

Does Skye Biologics have an API?

No public API is recorded for Skye Biologics.

What industry is Skye Biologics in?

Skye Biologics's product category is Regenerative Medicine Tissue Allografts. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Market ScoopAmniotic Products Market Poised for USD 2.4 Billion by 2033The global amniotic products market is projected to grow from USD 1.2 billion in 2023 to USD 2.4 billion by 2033, reflecting a compound annual growth rate of 7.3%, driven by increasing adoption of regenerative therapies in wound care, orthopedics, and ophthalmology. Cryopreserved amniotic membranes held over 52% market share in 2023, while hospitals represented the dominant end-use segment at more than 41%, and North America led regionally with a 34% share. Key players including MiMedx Group Inc., Integra Lifesciences Holdings Corporation, and Skye Biologics Inc. are advancing product innovation, though the market faces challenges from limited long-term clinical evidence, regulatory variations across regions, and high processing costs.PR.comAcademy Medical and Skye Biologics Partner to Strengthen Offering in Federally Funded Medical Facilities - PR.comAcademy Medical and Skye Biologics partnered to bring validated BioECM tissue biologics to over 2,000 VA, DoD, and HHS medical centers. The collaboration expands Skye's distribution network, with over 250,000 tissue grafts already utilized. The companies aim to provide next-generation biologics to military and government healthcare providers.PrwebArrowhead Health Centers at the Forefront of Pain Management with Use of Regenerative Cell-based Therapies to Treat Chronic PainArrowhead Health Centers launched its Total Joint Rejuvenation Program, offering a regenerative cell therapy for large joint osteoarthritis and degenerative spinal conditions. The procedure uses Skye Biologics PX50, an injectable matrix from placental tissue, and former NFL player Eric Dickerson underwent four injections for chronic back pain.